{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:39:39Z","timestamp":1790109579368,"version":"4.0.1"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo\u2010controlled, 12\u2010week trial in children (5\u2013&lt;12\u00a0years) and adolescents (12\u2013&lt;18\u00a0years) with OAB. MONKEY and MARMOSET were open\u2010label, 52\u2010week trials in children and adolescents or younger children (6\u00a0months\u2013&lt;5\u00a0years), respectively, with NDO. During the trials, solifenacin doses could be titrated to weight\u2010adjusted pediatric equivalent doses (PEDs) of 2.5, 5, 7.5, or 10\u00a0mg\u00a0day<jats:sup>\u20131<\/jats:sup>. Nonlinear mixed effects modeling was used to develop population PK models to characterize the PK in patients with either OAB or NDO. Overall, 194 children and adolescents received solifenacin. At the time of PK sampling, the majority (119\/164 [72.6%] patients) were receiving PED10 once daily. All population models included first\u2010order oral absorption, a lag time, and interindividual variability. PK analysis showed that apparent clearance was similar in both patient populations. Mean apparent oral plasma clearance (CL\/F), apparent volume of distribution during the terminal phase (V<jats:sub>z<\/jats:sub>\/F), and terminal half\u2010life (t<jats:sub>1\/2<\/jats:sub>) were higher in adolescents than in children, but median time to maximum plasma concentration (t<jats:sub>max<\/jats:sub>) was similar. Dose\u2010normalized exposure results were similar for both younger and older patients with OAB or NDO. In conclusion, population PK modeling was used to successfully characterize solifenacin PK in pediatric patients with OAB or NDO. Similar solifenacin PK characteristics were observed in both populations.<\/jats:p>","DOI":"10.1002\/prp2.684","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T05:04:59Z","timestamp":1606280699000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity"],"prefix":"10.1002","volume":"8","author":[{"given":"Stacey","family":"Tannenbaum","sequence":"first","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"den Adel","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Krauwinkel","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meijer","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hollestein\u2010Havelaar","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verheggen","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Newgreen","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22751"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22609"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.06.063"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07681.x"},{"key":"e_1_2_9_6_1","first-page":"107","article-title":"The prevalence of overactive bladder and nocturnal enuresis in Japanese early adolescents : a questionnaire survey","volume":"52","author":"Kajiwara M","year":"2006","journal-title":"Hinyokika Kiyo"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01217.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0691-z"},{"key":"e_1_2_9_10_1","first-page":"182","article-title":"Overactive bladder: pharmacologic treatments in the neurogenic population","volume":"10","author":"Kennelly MJ","year":"2008","journal-title":"Rev Urol"},{"key":"e_1_2_9_11_1","unstructured":"BurkhardFC BoschJLHR CruzF et al.EAU urinary incontinence guidelines 2018. Available athttps:\/\/uroweb.org\/guideline\/urinary\u2010incontinence\/(last accessed 16 June 2020)."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22248"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4337"},{"key":"e_1_2_9_14_1","unstructured":"Oxybutynin hydrochloride 5mg tablets: Summary of Product Characteristics (04 January 2018). Available athttps:\/\/www.medicines.org.uk\/emc\/product\/3005(last accessed 16 June 2020)."},{"key":"e_1_2_9_15_1","unstructured":"Regurin 20 mg coated tablets: Summary of Product Characteristics (25 June 2019). Available athttps:\/\/www.medicines.org.uk\/emc\/product\/6643(last accessed 16 June 2020)."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11654.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.015"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.08.485"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2012.164"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22945"},{"key":"e_1_2_9_21_1","unstructured":"FangG.Solifenacin oral suspension NDA (03 August 2017). Available athttps:\/\/www.fda.gov\/media\/107501\/download(last accessed 16 June 2020)."},{"key":"e_1_2_9_22_1","unstructured":"Astellas.News release. Astellas obtained approval for Vesicare OD in Japan. Available athttps:\/\/www.astellas.com\/system\/files\/news\/2018\u201006\/101027_eg_0.pdf(last accessed 16 June 2020)."},{"key":"e_1_2_9_23_1","unstructured":"Vesicare 10mg film\u2010coated tablets: Summary of Product Characteristics (13 November 2019). Available athttps:\/\/www.medicines.org.uk\/emc\/product\/7493(last accessed 16 June 2020)."},{"key":"e_1_2_9_24_1","unstructured":"Vesicare oral suspension: Summary of Product Characteristics (12 November 2019). Available athttps:\/\/www.medicines.org.uk\/emc\/product\/9518(last accessed 16 June 2020)."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.2.329"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.05.100"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.061"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.05.038"},{"key":"e_1_2_9_29_1","unstructured":"BosmanB TannenbaumS WinklewskiP denAdelM NewgreenD Baka\u2010OstrowskaM.A multicenter open\u2010label single\u2010dose study to evaluate the pharmacokinetics safety and tolerability of solifenacin succinate suspension in pediatric subjects from 5 to less than 18 years of age with neurogenic detrusor overactivity (NDO). Presented at ICS 2013 26\u201330 August 2013 Barcelona Spain. Available athttps:\/\/www.ics.org\/Abstracts\/Publish\/180\/000296.pdf(last accessed 16 June 2020)."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.1356"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2019.12.012"},{"key":"e_1_2_9_32_1","unstructured":"Astellas received approval for solifenacin oral suspension for pediatric patients in Europe. Available athttps:\/\/www.astellas.com\/en\/news\/10391(last accessed 16 June 2020)."},{"key":"e_1_2_9_33_1","unstructured":"FDA approves VESIcare LS\u2122 (solifenacin succinate) oral suspension for pediatric patients. Available athttps:\/\/www.astellas.com\/us\/news\/4931(last accessed 16 June 2020)."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004267592"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200405020-00002"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02097.x"},{"key":"e_1_2_9_37_1","unstructured":"Vesicare 5mg film\u2010coated tablets: Summary of Product Characteristics (13 November 2019). Available athttps:\/\/www.medicines.org.uk\/emc\/product\/5559(last accessed 16 June 2020)."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3010053"},{"key":"e_1_2_9_39_1","unstructured":"BosmanB StrougoA Van der Putten\u2010SlobI Vande WalleJ HoebekeP.A multicenter open\u2010label single ascending dose study to evaluate pharmacokinetics safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with overactive bladder. Presented at the ICCS ERIC BAPU Congress 2012 12\u201014 October 2012 London UK.2012."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00305-3"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.06.026"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0782-9"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00004"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2017.25.2.59"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0060754"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.09.093"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T12:45:48Z","timestamp":1693658748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/prp2.684"],"URL":"https:\/\/doi.org\/10.1002\/prp2.684","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"2019-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00684"}}